CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on May 26, 2016, Paul J. Rushton, Ph.D., the Company’s Vice President of Plant Biotechnology, gave a seminar to discuss 22nd Century’s novel Very Low Nicotine smoking cessation aid at Hofstra Northwell School of Medicine on the campus of Hofstra University in Hempstead, New York.
During the presentation, Dr. Rushton announced a new initiative to engage medical departments, medical professionals, and professors at prominent U.S. medical schools as part of a new effort by 22nd Century to inform health care professionals about the Company’s Very Low Nicotine products and their potential to revolutionize the options available for doctors to treat smoking addiction.
Dr. Rushton explained: “We are now in the regulatory and education phases for our Very Low Nicotine products as 22nd Century’s Very Low Nicotine cigarettes are currently under review with the FDA to become the first-ever Modified Risk Tobacco Product (MRTP), MAGIC 0 Very Low Nicotine cigarettes are launching in Europe and in Australia, and we are planning Phase III clinical trials for our ‘X-22’ prescription smoking cessation aid in development. Moving forward, of critical importance is introducing our products to medical professionals who treat patients and prescribe therapies to help their patients quit smoking.”
In other news, 22nd Century will make presentations at both the 2016 Marcum MicroCap Conference in New York City and the 6th Annual LD Micro Invitational in Los Angeles:
2016 Marcum MicroCap Conference
Location: Grand Hyatt, 109 East 42nd St, New York, NY 10017
22nd Century Presentation Date: June 1, 2016
6th Annual LD Micro Invitational
Location: Luxe Sunset Blvd Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049
22nd Century Presentation Date: June 8, 2016
Both by-invitation-only investor conferences focus on promising, undervalued companies in the microcap space. Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group, will deliver a formal presentation at each conference on the respective dates noted above. In addition, Mr. Sicignano will be available for one-on-one investor meetings at both conferences.
To arrange a one-on-one meeting with 22nd Century, please contact Andrew Haag at email@example.com or 1-866-976-4784.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. Visit www.xxiicentury.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed on February 18, 2016, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.